Navigation Links
Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,at Society Of Nuclear Medicine 2007 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 4, 2007 - Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that the company will present the results of several preclinical studies at the 54th annual meeting of the Society of Nuclear Medicine (SNM) in Washington, D.C. The presentations include data on Azedra(TM) (Ultratrace (131)I-MIBG), the company's clinical-stage, targeted radiotherapeutic candidate for the treatment of malignant neuroendocrine tumors; Zemiva, its lead molecular imaging pharmaceutical for imaging cardiac ischemia; and MIP-190, its molecular imaging pharmaceutical candidate that targets angiotensin converting enzyme for the detection of heart failure and vascular inflammatory disease. Data on the company's radiolabeled small molecule molecular imaging pharmaceutical, MIP-1072, for the detection and staging of prostate cancer, were presented on June 3rd. -0-
Abstract Title: Formulation comparisons and pharmacokinetics of high

                specific activity Ultratrace 131I-Iobenguane (mIBG)

                for therapy


Authors:        J. F. Kronauge(a1), J. A. Barrett(1), J. Qi(1),

                H. Mok(1), D. H. Hunter(2), C. Bensimon(4),

                S. Oelsner(4), J. P. Norenberg(3), T. Anderson(3),

                S. Gallo(1), S. M. Hiller(1), J. Joyal(1),

                N. S. Lee(1) and J. W. Babich(1);

                1. Molecular Insight Pharmaceuticals, Inc., Cambridge,

                Massachusetts; 2. University of Western Ontario,

                London, Ontario, Canada; 3. University of New Mexico,

                Albuquerque, New Mexico and 4. MDS Nordion, Kanata,

                Ontario, Canada.


Reference #:    335357


Publication No.: 1316 - Scientific Poster Session


Poster Section:  Dosimetry/Radiobiology Posters


Session Info:   "Meet the Author" II: Neurosciences, General Clinical

                Specialties, and Radiopharmaceutical Chemistry Posters

                Monday, June 4

    
            3:15 PM- 4:00 PM

                Hall E


-0-

Abstract Title: A comparison of Iodine-123 and Technetium-99m assays

                using dose calibrators


Authors:        D. L. Yokell(a), J. F. Kronauge, C. S. Kao and J. W.

                Babich; Development, Molecular Insight

                Pharmaceuticals, Inc., Cambridge, Massachusetts.


Reference #:    335015


Publication No.: 1835 - Scientific Poster Session


Poster Section: Instrumentation Posters


Session Info:   "Meet the Author" IV: Instrumentation & Data Analysis

                Posters

                Tuesday, June 5

                1:15 PM - 2:00 PM

                Hall E

-0-

Abstract Title: Synthesis and evaluation of a series of M(CO)3+

                (M=Tc,Re) lisinopril complexes for imaging angiotensin

                converting enzyme (ACE)


Authors:        F. J. Femia(a1), K. P. Maresca(1), S. M. Hillier(1),

                C. N. Zimmerman(1), J. L. Joyal(1), J. A. Barrett(1),

                T. Coleman(2), O. Aras(2), C. A. Foss(3),

                M. G. Pomper(3), V. Dilsizian(2), W. C. Eckelman(1)

                and J. W. Babich(1); 1. Molecular Insight

                Pharmaceuticals, Inc., Cambridge, Massachusetts;

                2. Nuclear Medicine, University of Maryland,

                Baltimore, Maryland and 3. Radiology, Johns Hopkins

                Medical Institutions, Baltimore, Maryland.


Reference #:    331898


Publication No.: 613 - Scientific Paper Session (Oral)


Session Info:   New Chemistry-Other II

                Wednesday, June 6

                9:45 AM - 11:15 AM

                Room 145A

On June 3rd, researchers at Molecular Insight also presented preclinical data on MIP-1072, a radiolabeled, small molecule molecular imaging pharmaceutical in development for diagnosis and staging of prostate cancer. MIP-1072 is designed to target prostate specific membrane antigen (PSMA), a protein found predominantly on prostate tumor cells. The paper, "Molecular Targeting of Prostate Cancer with Small Molecular Inhibitors of Prostate Specific Membrane Antigen," was honored by SNM with the 2007 Berson-Yalow Award for most original scientific abstract.

About Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticals (NASDAQ: MIPI) is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve healthcare for patients with life-threatening diseases. The company is focused on discovering, developing and commercializing innovative and targeted radiotherapeutics and molecular imaging pharmaceuticals with initial applications in the areas of oncology and cardiology. Its lead targeted radiotherapeutic product candidates, Azedra and Onalta, are being developed for detection and treatment of cancer. The company's lead molecular imaging pharmaceutical product candidate, Zemiva, is being developed for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. In addition, the company has a growing pipeline of product candidates resulting from application of its proprietary platform technologies to new and existing compounds. Molecular Insight Pharmaceuticals is based in Cambridge, Massachusetts and its website address is: www.molecularinsight.com.

Forward-Looking Statements

Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about the development of Azedra(TM), Onalta (TM), Zemiva(TM) and our other product candidates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Molecular Insight to be materially different from historical result s or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Molecular Insight undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

Contact

Molecular Insight Pharmaceuticals, Inc.
Priscilla Harlan, 617-492-5554
Vice President, Corporate Communications
& Investor Relations


'"/>




Related medicine technology :

1. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
2. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
3. Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria
4. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
5. Avid Announces Results of AV-1 Molecular Imaging Agent for Alzheimers Disease Presented at AD/PD Meeting
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Revolutionary technology includes multi-speaker listening to ... leaders in advanced audiology and hearing aid technology, has ... the world,s first internet connected hearing aid that opens ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... firsts,: , TwinLink™ - the first dual ...
(Date:6/23/2016)... MEDIA, Pa. , June 23, 2016 ... treatments in an outpatient dialysis facility.  Treatments are usually ... to 6 hours per visit, including travel time, equipment ... on a patient, but especially grueling for patients who ... residents of a skilled nursing and rehabilitation centers for ...
(Date:6/23/2016)... 2016  Experian Health, the healthcare industry ... patient payment and care experience, today announced ... and services that will enhance the breadth ... These award-winning solutions will enable healthcare professionals ... in an ever-changing environment and redefine front-office ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 27, 2016 , ... "FCPX editors can now reveal their media with growing ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings ... users can now reveal the media of their split screens with growing colorful panels. ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their ... Eyeglasses . , Millions of individuals in the United States and Canada wear eyeglasses. ... way to both correct vision and make a fashion statement. Even celebrities use glasses ...
(Date:6/26/2016)... ... 26, 2016 , ... PawPaws brand pet supplements owned by Whole ... enhance the health of felines. The formula is all-natural and is made from Chinese ... PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
Breaking Medicine News(10 mins):